The proportion of prostate-specific antigen (PSA) complexed to α1-antichymotrypsin improves the discrimination between prostate cancer and benign prostatic hyperplasia in men with a total PSA of 10 to 30 μg/L

Clinical Chemistry

Volumn 48, Issue 8, 2002, Pages 1251-1256

  Martínez, Manuel ^a   España, Francisco ^a   Royo, Montserrat ^a   Alapont, José M ^a   Navarro, Silvia ^a   Estellés, Amparo ^a   Aznar, Justo ^a   Vera, César ^a   Jiménez Cruz, Juan F ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; COMPLEX FORMATION; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN CONTENT; SENSITIVITY AND SPECIFICITY; STOICHIOMETRY;

EID: 0036323865     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/48.8.1251     Document Type: Article

References (37)

1. Relative value of prostate-specific antigen and prostatic acid phosphatase in diagnosis and management of adenocarcinoma of prostate. Ohio State University experience
2. The value of serum prostate specific antigen determinations before and after radical prostatectomy
3. Prostate specific antigen density: A means of distinguishing benign prostatic hypertrophy and prostate cancer
4. Comparison of prostate-specific antigen corrected for total prostate volume and transition zone volume in a population-based screening study
5. Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease
6. Serum prostate specific antigen in a community based population of healthy men: Establishment of age-specific reference ranges
7. 1-antichymotrypsin
8. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer
9. Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with α-1-antichymotrypsin
10. 2-macroglobulin complexes in prostate cancer patient sera
11. Prostate-specific antigen forms a complex with and cleaves α-1-protease inhibitor in vitro
12. Molecular forms of prostate specific antigen and the human kallikrein gene family: A new era
13. 2-macroglobulin
14. 1-antichymotrypsin in the plasma of patients with prostatic disease
15. 1-antichymotrypsin as an indicator of prostate cancer
16. Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: Studies in serum and plasma samples
17. Free and complexed prostate-specific antigen: In vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-α-1-antichymotrypsin complex
18. Reference ranges for the concentrations of total and complexed plasma prostate-specific antigen and their ratio in patients with benign prostate hyperplasia
19. Longitudinal evaluation of the complexed-to-total prostate specific antigen ratio in men with prostate disease. Effect of treatment
20. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system
21. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6,630 men
22. Estimation of prostate cancer probability by logistic regression: Free and total prostate-specific antigen, digital rectal examination, and heredity are significant variables
23. 1-antichymotrypsin in the early detection of prostate cancer
24. Toward a checklist for reporting of studies of diagnostic accuracy of medical tests
25. Measurement of the proportion of free to total prostate specific antigen improves diagnostic performance of prostate specific antigen in the diagnostic gray zone of total prostate specific antigen
26. Evaluation of percentage of free serum prostate specific antigen to improve specificity of prostate cancer screening
27. The value of screening tests in the detection of prostate cancer. Part II. Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference range, and PSA density
28. Does free to total ratio of prostate-specific antigen alter decision-making on prostate biopsy?
29. Free and complexed prostatic-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia
30. A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: The best case scenario
31. Clinical evaluation of free PSA/total PSA (prostate-specific antigen) ratio in the diagnosis of prostate cancer
32. Comparison of percent free prostate specific antigen and prostate specific density as methods to enhance prostate specific antigen specificity in early prostate detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng/mL
33. Novel immunoassay for the measurement of complexed prostate-specific antigen in serum
34. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer
35. Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: Relationship to transition zone volume
36. 1-protease inhibitor for screening prostate cancer
37. Serial prostatic biopsies in men with persistently elevated serum prostatic specific antigen values